Venetoclax is a targeted oral cancer medication used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. It works by inhibiting the BCL-2 protein, which helps cancer cells die naturally. It is grouped under the following drug class(es): Antineoplastic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Venclexta, Venclyxto and Venetoclaxum. Its PubChem CID is 49846579.
Venetoclax
| CAS No | 1257044-40-8 |
|---|---|
| Molecular Formula | C45H50ClN7O7S |
| Molecular Weight | 868.4 g/mol |
| Synonyms | 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Venetoclax is a targeted oral cancer medication used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. It works by inhibiting the BCL-2 protein, which helps cancer cells die naturally.
The listed CAS number is 1257044-40-8.
The listed molecular formula is C45H50ClN7O7S.
The listed molecular weight is 868.4 g/mol.
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.
The source lists Venclexta, Venclyxto and Venetoclaxum.